GSK selected an undisclosed hepatology siRNA candidate from its collaboration with Wave Life Sciences for transfer into GSK’s development pipeline. The selection triggers a $12 million payment to Wave; each collaboration program can generate…
Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave Life Sciences and its allele-selective antisense oligonucleotide candidate, WVE-003.The key distinction is biological selectivity. Tominersen was designed to lower total…
Wave Life Sciences reported positive updated data from the RestorAATion-2 study of WVE-006, demonstrating substantial restoration of functional alpha-1 antitrypsin protein and significant reduction of toxic mutant protein in Alpha-1 Antitrypsin Deficiency (AATD).
